Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Modulus’ Convergent Design™ platform combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Seattle, Wa 98103, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Seattle, WA
Modulus Therapeutics Questions
Modulus Therapeutics's website is http://www.modulustherapeutics.com
Modulus Therapeutics's LinkedIn profile is https://www.linkedin.com/company/modulus-therapeutics
Modulus Therapeutics has
1 employees.
View email and phone details for 1
employees at Modulus Therapeutics.
Modulus Therapeutics's industry is
Biotechnology Research
Modulus Therapeutics's top competitors are
Outpace Bio,
Tune Therapeutics,
Evexia Bio Fund,
Ozette,
Sonoma Biotherapeutics, Inc.,
Myosana Therapeutics, Inc,
Oisin Biotechnologies,
Quantpi,
Shape Therapeutics Inc.,
Kinea Bio.
Modulus Therapeutics's categories are Biotechnology Research
Modulus Therapeutics's founding year is 2020
